

Resource Summary Report

Generated by [NIF](#) on Sep 8, 2026

CD8a Monoclonal Antibody (53-6.7), PE-Cyanine7, eBioscience

RRID:AB_469584

Type: Antibody

Proper Citation

Thermo Fisher Scientific Cat# 25-0081-82, RRID:AB_469584

Antibody Information

URL: http://antibodyregistry.org/AB_469584

Proper Citation: Thermo Fisher Scientific Cat# 25-0081-82, RRID:AB_469584

Target Antigen: CD8a

Host Organism: rat

Clonality: monoclonal

Comments: Applications: Flow
Consolidation on 1/2020: AB_469584, AB_10113390

Antibody Name: CD8a Monoclonal Antibody (53-6.7), PE-Cyanine7, eBioscience

Description: This monoclonal targets CD8a

Target Organism: mouse

Clone ID: Clone 53-6.7

Antibody ID: AB_469584

Vendor: Thermo Fisher Scientific

Catalog Number: 25-0081-82

Record Creation Time: 20251213T073809+0000

Record Last Update: 20260903T215520+0000

Ratings and Alerts

No rating or validation information has been found for CD8a Monoclonal Antibody (53-6.7), PE-Cyanine7, eBioscience.

No alerts have been found for CD8a Monoclonal Antibody (53-6.7), PE-Cyanine7, eBioscience.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 63 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#).

Bajbouj K, et al. (2026) Targeted Lipid Nanoparticle Delivery of FAP-CAR mRNA Enables Potent In Vivo T-cell Engineering against Pancreatic Tumors. *Cancer immunology research*, 14(4), 559.

Palmer P, et al. (2026) A computational method to design broad-spectrum T cell-inducing vaccines applied to Betacoronaviruses. *Cell reports methods*, 101508.

Luo Y, et al. (2026) CCL5 deficiency aggravates acute DSS-induced colitis by restricting IL-33-induced formation of Tregs in intestinal tract. *Clinical science (London, England : 1979)*, 140(1).

Laubreton D, et al. (2026) Transient tumor exposure induces persistent functional defects in memory CD8+ T cells. *iScience*, 29(5), 115556.

Murakami R, et al. (2026) Foxp3 and BATF cooperatively direct cis-regulatory programs and gene expression for effector Treg cell differentiation. *Immunity*, 59(5), 1253.

Westfall S, et al. (2025) A type 1 immune-stromal cell network mediates disease tolerance against intestinal infection. *Cell*, 188(12), 3135.

Marchand T, et al. (2025) Periosteal skeletal stem cells can migrate into the bone marrow and support hematopoiesis after injury. *eLife*, 13.

Sahasrabuddhe AA, et al. (2025) The FBXO45-GEF-H1 Axis Controls Germinal Center Formation and B-cell Lymphomagenesis. *Cancer discovery*, 15(4), 838.

Longo J, et al. (2025) Glucose-dependent glycosphingolipid biosynthesis fuels CD8+ T cell function and tumor control. *Cell metabolism*, 37(9), 1890.

Braun LM, et al. (2025) Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity. *Cancer cell*, 43(2), 269.

Léger J, et al. (2025) The transcription factor NFIL3 drives innate lymphoid cell specification from lymphoid progenitors. *Immunity*, 58(11), 2685.

Cai W, et al. (2025) The gut microbiota promotes pain in fibromyalgia. *Neuron*, 113(13), 2161.

Yagi M, et al. (2025) Bivalent chromatin instructs lineage specification during hematopoiesis. *Cell*, 188(16), 4314.

Wang F, et al. (2025) An age-related decrease in leptin contributes to CD8⁺ T cell aging in the tumor microenvironment. *Cell reports. Medicine*, 6(9), 102310.

Rennen S, et al. (2025) Lipid nanoparticles as a tool to dissect dendritic cell maturation pathways. *Cell reports*, 44(8), 116150.

Baptista AP, et al. (2025) TLR ligand sensing by lymph node FRCs directs intranodal lymphocyte accumulation to promote immune responses. *iScience*, 28(11), 113734.

Ding R, et al. (2024) Lactate modulates RNA splicing to promote CTLA-4 expression in tumor-infiltrating regulatory T cells. *Immunity*, 57(3), 528.

Lee KJ, et al. (2024) IL-7-primed bystander CD8 tumor-infiltrating lymphocytes optimize the antitumor efficacy of T cell engager immunotherapy. *Cell reports. Medicine*, 5(5), 101567.

Fay M, et al. (2024) TGF- β neutralization attenuates tumor residency of activated T cells to enhance systemic immunity in mice. *iScience*, 27(8), 110520.

Dai D, et al. (2024) Chemoradiotherapy-induced ACKR2⁺ tumor cells drive CD8⁺ T cell senescence and cervical cancer recurrence. *Cell reports. Medicine*, 5(5), 101550.